VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) and Guardian Pharmacy Services (NYSE:GRDN – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.
Earnings & Valuation
This table compares VYNE Therapeutics and Guardian Pharmacy Services”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| VYNE Therapeutics | $570,000.00 | 33.29 | -$26.48 million | ($0.38) | -74.54 |
| Guardian Pharmacy Services | $1.45 billion | 1.40 | $49.22 million | $0.83 | 48.95 |
Profitability
This table compares VYNE Therapeutics and Guardian Pharmacy Services’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| VYNE Therapeutics | -4,726.21% | -70.42% | -63.46% |
| Guardian Pharmacy Services | 3.64% | 30.72% | 15.99% |
Institutional and Insider Ownership
83.8% of VYNE Therapeutics shares are owned by institutional investors. 3.0% of VYNE Therapeutics shares are owned by company insiders. Comparatively, 33.0% of Guardian Pharmacy Services shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
VYNE Therapeutics has a beta of 2, meaning that its share price is 100% more volatile than the S&P 500. Comparatively, Guardian Pharmacy Services has a beta of 0.1, meaning that its share price is 90% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for VYNE Therapeutics and Guardian Pharmacy Services, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VYNE Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Guardian Pharmacy Services | 0 | 2 | 7 | 0 | 2.78 |
Guardian Pharmacy Services has a consensus target price of $42.83, indicating a potential upside of 5.44%. Given Guardian Pharmacy Services’ stronger consensus rating and higher probable upside, analysts plainly believe Guardian Pharmacy Services is more favorable than VYNE Therapeutics.
Summary
Guardian Pharmacy Services beats VYNE Therapeutics on 11 of the 14 factors compared between the two stocks.
About VYNE Therapeutics
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
About Guardian Pharmacy Services
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.
Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
